Status:
TERMINATED
Study Evaluating Mitoxantrone in Multiple Sclerosis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Secondary Progressive Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the saf...
Eligibility Criteria
Inclusion
- Secondary progressive MS in an active stage
- EDSS between 3 and 6
Exclusion
- Benign or primary progressive MS
- Patients with cardiac risk factors
- Patients who have already received mitoxantrone
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT00146159
Start Date
March 1 2005
Last Update
December 28 2007
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Berg, Germany, D-82335
2
Berlin, Germany, D-13347
3
Düsseldorf, Germany, D-40225
4
Düsseldorf, Germany, D-40479